🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "major milestone" in the battle against superbug strains of the pathogen, according to scientists.

A Worldwide Public Health Issue

Cases of gonorrhoea are increasing globally, with figures suggesting over 82 million new cases each year. Especially elevated rates are observed in Africa and nations within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely development in the context of rising global incidence, increasing antimicrobial resistance and the very limited available drugs at this time.”

Medical experts are deeply concerned about the surge in treatment-resistant strains. The World Health Organization has classified it as a "high-priority threat". Ongoing monitoring found that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Secure Approval

Zoliflodacin, alternatively called a brand name, was authorized by the US FDA in December for treating gonorrhoea. This infection can lead to significant complications, including infertility. Researchers anticipate that specific application of this new drug will help slow the emergence of superbugs.

Gepotidacin, created by the pharmaceutical company GSK, was also approved in close succession. This medication, which is also used to treat urinary tract infections, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin was the result of a innovative non-profit model for drug creation. The non-profit organisation GARDP partnered with the drug firm its industry partner to bring it to fruition.

“This authorization marks a major breakthrough in the treatment of superbug gonorrhoea, which until now has been evolving faster than medical innovation.”

Research Study Data and Global Access

Based on data published in a prominent scientific publication, the new drug successfully treated the vast majority of cases of the STI. This places it at an equal footing with the existing first-line therapy, which uses an injection and a pill. The research enrolled hundreds of participants from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, GARDP has the ability to license and sell the drug in numerous low-income and middle-income countries.

Clinicians directly involved have expressed hope. The availability of a single-dose, oral treatment such as this is described as a "critical tool" for gonorrhoea control. This is considered vital to reduce the burden of the infection for patients and to stop the proliferation of extremely resistant gonorrhoea worldwide.